|
1
|
Kohler BA, Ward E, McCarthy BJ, et al:
Annual report to the nation on the status of cancer, 1975–2007,
featuring tumors of the brain and other nervous system. J Natl
Cancer Inst. 103:714–736. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang YC, Wei LJ, Liu JT, Li SX and Wang
QS: Comparison of cancer incidence between China and the USA.
Cancer Biol Med. 9:128–132. 2012.PubMed/NCBI
|
|
3
|
Linos E, Spanos D, Rosner BA, Linos K,
Hesketh T, Qu JD, Gao YT, Zheng W and Colditz GA: Effects of
reproductive and demographic changes on breast cancer incidence in
China: A modeling analysis. J Natl Cancer Inst. 100:1352–1360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li CI, Anderson BO, Daling JR and Moe RE:
Trends in incidence rates of invasive lobular and ductal breast
carcinoma. JAMA. 289:1421–1424. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McPherson K, Steel CM and Dixon JM: ABC of
breast diseases. Breast cancer-epidemiology, risk factors, and
genetics. BMJ. 321:624–628. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chia KS, Reilly M, Tan CS, Lee J, Pawitan
Y, Adami HO, Hall P and Mow B: Profound changes in breast cancer
incidence may reflect changes into a Westernized lifestyle: A
comparative population-based study in Singapore and Sweden. Int J
Cancer. 113:302–306. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McDonnell DP, Park S, Goulet MT, Jasper J,
Wardell SE, Chang CY, Norris JD, Guyton JR and Nelson ER: Obesity,
cholesterol metabolism and breast cancer pathogenesis. Cancer Res.
74:4976–4982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang J, Lu JP, Suter DM, Krause KH, Fini
ME, Chen B and Lu Q: Isoform- and dose-sensitive feedback
interactions between paired box 6 gene and delta-catenin in cell
differentiation and death. Exp Cell Res. 316:1070–1081. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Huang CT, Chen J, et al: Pax6 is
a human neuroectoderm cell fate determinant. Cell Stem Cell.
7:90–100. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shyr CR, Tsai MY, Yeh S, Kang HY, Chang
YC, Wong PL, Huang CC, Huang KE and Chang C: Tumor suppressor PAX6
functions as androgen receptor co-repressor to inhibit prostate
cancer growth. Prostate. 70:190–199. 2010.PubMed/NCBI
|
|
12
|
Muratovska A, Zhou C, He S, Goodyer P and
Eccles MR: Paired-Box genes are frequently expressed in cancer and
often required for cancer cell survival. Oncogene. 22:7989–7997.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moelans CB, Verschuur-Maes AH and van
Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6,
PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast
cancer. J Pathol. 225:222–231. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zong X, Yang H, Yu Y, Zou D, Ling Z, He X
and Meng X: Possible role of Pax-6 in promoting breast cancer cell
proliferation and tumorigenesis. BMB Rep. 44:595–600. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sobin LH and Wittekind CH: TNM
Classification of Malignant tumours6th. John Wiley & Sons;
Hoboken, NJ, USA: 2002
|
|
16
|
Zhang B, Cao X, Liu Y, et al:
Tumor-derived matrix metalloproteinase-13 (MMP-13) correlates with
poor prognoses of invasive breast cancer. BMC Cancer. 8:832008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lang D, Powell SK, Plummer RS, Young KP
and Ruggeri BA: PAX genes: Roles in development, pathophysiology,
and cancer. Biochem Pharmacol. 73:1–14. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang Q, Shao Y, Shi J, Qu Y, Wu K, Dang S,
Shi B and Hou P: Concomitant PIK3CA amplification and RASSF1A or
PAX6 hypermethylation predict worse survival in gastric cancer.
Clin Biochem. 47:111–116. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yao D, Shi J, Shi B, et al: Quantitative
assessment of gene methylation and their impact on clinical outcome
in gastric cancer. Clin Chim Acta. 413:787–794. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Selvarajah S, Pyne S, Chen E, et al:
High-resolution array CGH and gene expression profiling of alveolar
soft part sarcoma. Clin Cancer Res. 20:1521–1530. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mascarenhas JB, Young KP, Littlejohn EL,
Yoo BK, Salgia R and Lang D: PAX6 is expressed in pancreatic cancer
and actively participates in cancer progression through activation
of the MET tyrosine kinase receptor gene. J Biol Chem.
284:27524–27532. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhou YH, Wu X, Tan F, et al: PAX6
suppresses growth of human glioblastoma cells. J Neurooncol.
71:223–229. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou YH, Tan F, Hess KR and Yung WK: The
expression of PAX6, PTEN, vascular endothelial growth factor, and
epidermal growth factor receptor in gliomas: relationship to tumor
grade and survival. Clin Cancer Res. 9:3369–3375. 2003.PubMed/NCBI
|
|
24
|
Chen L, Romond E, Chokshi S, Saeed H,
Hodskins J, Stevens M, Pasley G, Weiss H and Massarweh S: A
prognostic model of early breast cancer relapse after standard
adjuvant therapy and comparison with metastatic disease on initial
presentation. Breast Cancer Res Treat. 136:565–572. 2012.
View Article : Google Scholar : PubMed/NCBI
|
